Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Benitec Biopharma Limited (BNTC) had Stock-Based Compensation of $12.56M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-11.84M |
|
-- |
|
-- |
|
$13.38M |
|
$-13.38M |
|
$1.54M |
|
$-11.84M |
|
$-11.84M |
|
$-11.84M |
|
$-11.84M |
|
$-11.84M |
|
$-11.84M |
|
$-13.38M |
|
$-13.36M |
|
45.97M |
|
45.97M |
|
$-0.26 |
|
$-0.26 |
|
| Balance Sheet Financials | |
$189.59M |
|
$0.12M |
|
$1.09M |
|
$190.68M |
|
$2.80M |
|
$0.52M |
|
$0.52M |
|
$3.32M |
|
$187.36M |
|
$187.36M |
|
$187.36M |
|
34.26M |
|
| Cash Flow Statement Financials | |
$-7.13M |
|
$-0.01M |
|
$98.23M |
|
$97.86M |
|
$188.90M |
|
$91.05M |
|
|
Stock-Based Compensation |
$12.56M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
67.69 |
|
-- |
|
-- |
|
0.00 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.32% |
|
-6.32% |
|
-6.21% |
|
-6.30% |
|
$5.47 |
|
$-0.16 |
|
$-0.15 |
|